Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

X-linked Hypophosphatemia

What is X-linked Hypophosphatemia?

X-linked hypophosphatemia (XLH) is an inherited disorder caused by mutations in the PHEX gene on the X chromosome. This gene is responsible for encoding a protein involved in regulating blood phosphate levels. As a result, XLH is characterized by low phosphate levels. Phosphate works closely with calcium to maintain bone health. XLH is the most common genetic cause of rickets (weakening and softening of bones in children). It may cause no symptoms or lead to soft, weak, painful bones, bowed legs, short stature, teeth-related pain, and spontaneous dental abscesses. XLH typically presents by the age of two due to leg bowing as a result of weight-bearing and walking. It may also present later as short stature or in adulthood due to bone and joint pain and immobility associated with the calcification of tendons and ligaments. Treatment includes phosphate and vitamin D supplements and potentially growth hormone supplements and surgery, depending on the type and severity of symptoms.

 

Synonyms

  • X-linked Hypophosphatemia
  • X-linked Hypophosphatemia
  • X-linked Dominant Hypophosphatemic Rickets
  • X-linked Hypophosphatemia
  • X-linked Hypophosphatemia
  • X-linked Vitamin D-resistant Rickets
  • Hypophosphatemic Vitamin D-resistant Rickets
  • X-linked Hypophosphatemia

X-linked hypophosphatemia (XLH) is an inherited disorder caused by mutations in the PHEX gene on the X chromosome. This gene is responsible for encoding a protein involved in regulating blood phosphate levels. As a result, XLH is characterized by low phosphate levels. Phosphate works closely with calcium to maintain bone health. XLH is the most common genetic cause of rickets (weakening and softening of bones in children). It may cause no symptoms or lead to soft, weak, painful bones, bowed legs, short stature, teeth-related pain, and spontaneous dental abscesses. XLH typically presents by the age of two due to leg bowing as a result of weight-bearing and walking. It may also present later as short stature or in adulthood due to bone and joint pain and immobility associated with the calcification of tendons and ligaments. Treatment includes phosphate and vitamin D supplements and potentially growth hormone supplements and surgery, depending on the type and severity of symptoms.

Acknowledgement of X-linked Hypophosphatemia has not been added yet.

XLH is estimated to occur in 3.9-5 individuals per 100,000 live births. Males and females are equally affected.

 

Name Abbreviation
X-linked Hypophosphatemia XLH
X-linked Hypophosphatemia Hypophosphatemic rickets
X-linked Dominant Hypophosphatemic Rickets XLHR
X-linked Hypophosphatemia X-linked Rickets
X-linked Hypophosphatemia Vitamin D Resistant Rickets
X-linked Vitamin D-resistant Rickets VDRR
Hypophosphatemic Vitamin D-resistant Rickets HPDR
X-linked Hypophosphatemia Familial Hypophosphatemic Rickets

XLH is caused by changes in the PHEX gene. The exact cause of XLH and the function of the protein encoded by PHEX is unknown, but this protein is found in cells responsible for bone formation. Changes in this gene lead to abnormally high levels of another protein called fibroblast growth factor 23 (FGF23). This protein increases the secretion of phosphate into the urine in the kidneys, leading to low phosphate levels due to its urinary excretion. In addition, FGF23 also decreases the activity of an enzyme in the kidney that activates vitamin D. Therefore, with high levels of FGF23, vitamin D is not activated adequately, impairing its function. Phosphate and vitamin D both have important functions in maintaining bone health, therefore, their dysregulation leads to skeletal symptoms.

Human cells contain 23 pairs of chromosomes, including sex chromosomes, which can be X or Y. An individual is genetically male if they have an X chromosome and Y chromosome and female if they have two X chromosomes. One copy of each chromosome pair is inherited from the mother and one copy from the father. The offspring becomes genetically male if they happen to inherit a Y chromosome from their father and female if they inherit an X chromosome from their father. While the other 22 pairs of chromosomes have very similar content, the X chromosome is much larger than the Y chromosome, and therefore, contains many more genes. XLH is inherited in an X-linked manner, as the responsible gene is located on the X chromosome. An implication of an X-linked pattern of inheritance is that an affected father will pass on XLH to all his daughters but none of his sons while an affected mother passes it on to 50% of her children. XLH is also a dominant disorder, meaning that having one defective X chromosome is enough to cause XLH.

Although in most cases XLH is inherited, and thus, runs in families, there are cases where it occurs in individuals with no family history.

 

XLH syndromes can range from asymptomatic hypophosphatemia that is only evident in blood tests measuring blood phosphate to severe bone abnormalities and pain. In most cases, symptoms become evident around 2 years of age as the individual starts walking and weight-bearing more. Abnormal development of the bones, particularly bowing or twisted growth of lower legs and slow growth are common early presentations. Other symptoms are bone pain, muscle pain and weakness, or an abnormal way of walking (gait). Pain may worsen at night or with prolonged walking. Sometimes, XLH may present in adulthood with symptoms such as short stature with disproportionately shorter legs, joint pain, or reduced joint immobility due to the hardening of tendons and ligaments (enthesopathy). Dental abnormalities are also common. Because teeth cannot mineralize properly, there is a higher risk for tooth abscesses and tooth pain. There might be craniosynostosis which is the early fusion of the bones that make up the skull before the brain has fully developed leading to irregularities in the shape of the skull or Chiari malformation which is when a part of the brain pushes down into the spinal canal because the space in the skull is too small for the brain, causing headaches. Hearing impairment is also possible as an abnormal skull may impinge in the auditory nerve.

 

Diagnosis of XLH is suspected based on family history, symptoms and clinical features such as slow growth velocity, worsening bowing of lower legs which starts when the child begins walking, or swelling around joints in children and short stature, bone and joint pain and immobility and dental issues in adults. Once there is a clinical suspicion due to the presence of these features, X-ray imaging of the bones and blood tests can confirm XLH. Genetic testing is also available but not necessary for diagnosis.

 

Biochemical tests that establish the diagnosis of XLH include blood tests measuring phosphate levels. In XLH, blood phosphate levels are abnormally low. As opposed to the vitamin D-related causes of disorders with a similar presentation, phosphate levels in XLH do not improve with vitamin D treatment. Additionally, while in healthy individuals, active vitamin D levels rise in the body in response to low phosphate levels, such a response is not observed in individuals with XLH, leading to vitamin D levels that do not correspond to the low phosphate levels. Urine tests are also done to check for phosphate wasting which is expected in XLH. This means that despite low phosphate levels in the blood, phosphate is being excreted in the urine while the body should be trying to reduce the amount of phosphate excreted in the urine to correct the low blood phosphate levels. Therefore, XLH is associated with low blood phosphate levels and elevated urine phosphate. Other test results that can assist an XLH diagnosis include elevated FGF23 levels in the blood and elevated ALP, particularly in children, which is a marker of activation of cells that form bones in response to poor bone mineralization. 

Another important investigation in XLH is an x-ray which may show bone abnormalities such as the enlargement of the wide end of the long bones.

Genetic testing can also identify mutations in PHEX but this is not necessary for diagnosis.

 

Treatment of XLH consists of active vitamin D (calcitriol) and phosphate supplements. This is associated with reduced pain and improved lower leg abnormalities. In children, treatment starts at the time of diagnosis and is continued until the completion of long bone growth. In adults, however, it is unclear whether medical treatment is beneficial and it is reserved for adults with significant symptoms such as severe pain, planned orthopedic procedure, test results indicating the softening of the bones or osteomalacia (elevated ALP), or multiple fractures that occur due to overuse and not trauma (stress fractures). 

Burosumab is another pharmacological option for XLH. Burosumab is a monoclonal anti-FGF23 antibody. Antibodies are proteins made by the immune system to attack foreign particles that are in the body. Monoclonal antibodies are engineered antibodies that attack a specific substance. Burosumab attacks FGF23 which is elevated in XLH and thus causes all the associated symptoms. The immune-mediated destruction of the extra FGF23 improves hypophosphatemia and many of the associated symptoms. 

In addition, children with short stature may benefit from growth hormone therapy to increase their final height if their XLH is well-controlled. This, however, is controversial. 

Some individuals with severe lower leg deformities that do not respond to pharmacologic treatment may benefit from surgical treatment. Although there are multiple surgical options, the effectiveness of these has not been compared. When choosing the surgical option, it is important to consider the age and the growth status of the individual. For example, corrective osteotomy or cutting of the bone to reshape and restore the correct alignment of the bone is typically not done until after peak growth velocity has been achieved. Peak growth velocity refers to a period of time in which a child experiences the fastest growth in height and is determined by following a child’s growth by charting their height at specific ages which tends to have a predictable pattern. 

Regular dental hygiene such as flossing and using a fluoride mouthwash is essential to prevent dental problems.

 

The prognosis of XLH varies significantly among individuals. Some may only have low phosphate levels with no associated symptoms while others may experience severe pain, complications, and persistent lower leg deformity despite treatment. The persistence of lower leg abnormalities in adulthood despite appropriate management is partially related to poor compliance with pharmacological therapy during childhood. In addition, early diagnosis and treatment also improve long-term outcomes.

Tips or Suggestions of X-linked Hypophosphatemia has not been added yet.

Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res. 2011 Jul;26(7):1381-8. doi: 10.1002/jbmr.340. 

 

Fuente R, Gil-Peña H, Claramunt-Taberner D. X-linked hypophosphatemia and growth. Rev Endocr Metab Disord. 2017;18(1):107-115. DOI 10.1007/s11154-017-9408-1

 

Genetic and Rare Disease Information Center. X-Linked Hypophosphatemia. 2018. Available from  https://rarediseases.info.nih.gov/diseases/12943/x-linked-hypophosphatemia
 

Lambert AS, Zhukouskaya V, Rothenbuhler A, Linglart A. X-linked hypophosphatemia: Management and treatment prospects. Joint Bone Spine. 2019;86(6):731-738. https://doi.org/10.1016/j.jbspin.2019.01.012.

 

Ruppe MD. X-Linked Hypophosphatemia. 2012. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK83985/

 

Community Details Update Created by RareshareTeam
Last updated 25 Oct 2021, 02:52 PM

Posted by RareshareTeam
25 Oct 2021, 02:52 PM

Hi everyone,

The X-Linked Hypophosphatemia community details have been updated. We added more information about the cause, prevalence, symptoms, diagnosis, and treatment. Hopefully, you find it helpful. 

Diagnosis Created by shannon.ashoori
Last updated 1 Jul 2020, 01:02 AM

Posted by shannon.ashoori
1 Jul 2020, 01:02 AM

Check out this article about Karabeth Souza, an eighth grader living with X-Linked Hypophosphatemia . Souza’s parents noticed something was wrong when she was having trouble walking at 18 months. Shortly thereafter, she was diagnosed with X-Linked Hypophosphatemia. When were you first diagnosed with XLH? How did you cope with the news?

Help with new XLH support website Created by LucyBanwell
Last updated 10 Jan 2017, 05:18 PM

Posted by LucyBanwell
10 Jan 2017, 05:18 PM

Hi there I am a journalist working on a new UK-based support website for people with XLH (X-linked hypophosphatemia – a form of rickets). I am looking for case studies for the website. People who would be happy to share their experience of living with the disease in order to help other sufferers. There is a fee involved to cover your time. Please do get in touch if you have XLH or have a family member with the condition. NB this is a time sensitive request posted on 10 January 2017. Please email me at lucy@lucybanwell.com All the best Lucy Banwell, Freelance Journalist

Community External News Link
Title Date Link
Lewisville family helps to raise awareness for rare disease 07/01/2020
Community Resources
Title Description Date Link

Clinical Trials


Cords registry

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access.

Enrolling is easy.

  1. Complete the screening form.
  2. Review the informed consent.
  3. Answer the permission and data sharing questions.

After these steps, the enrollment process is complete. All other questions are voluntary. However, these questions are important to patients and their families to create awareness as well as to researchers to study rare diseases. This is why we ask our participants to update their information annually or anytime changes to their information occur.

Researchers can contact CoRDS to determine if the registry contains participants with the rare disease they are researching. If the researcher determines there is a sufficient number of participants or data on the rare disease of interest within the registry, the researcher can apply for access. Upon approval from the CoRDS Scientific Advisory Board, CoRDS staff will reach out to participants on behalf of the researcher. It is then up to the participant to determine if they would like to join the study.

Visit sanfordresearch.org/CoRDS to enroll.

Community Leaders

 

Expert Questions

Ask a question

Community User List

Hi there

 

I am a journalist working on a new UK-based support website for people with XLH (X-linked hypophosphatemia - a form of rickets). I am looking for case studies for the website. People...
Passionate about IT and technology, calm personality, very shy.
Was born with a mutant version of clinked hypophosphatemia. I was also diagnosed as a child with rickets and blount's disease. As an adult I have gout, osteomalacia, colitis, vitiligo, and neuroma...

Start a Community


Don't See Your Condition On Rareshare?

Start your own! With a worldwide network of 8,000 users, you won't be the only member of your community for long.

FAQ


Have questions about rareshare?

Visit our Frequently Asked Questions page to find the answers to some of the most commonly asked questions.

Discussion Forum

Community Details Update

Created by RareshareTeam | Last updated 25 Oct 2021, 02:52 PM

Diagnosis

Created by shannon.ashoori | Last updated 1 Jul 2020, 01:02 AM

Help with new XLH support website

Created by LucyBanwell | Last updated 10 Jan 2017, 05:18 PM


Communities

Our Communities

Join Rareshare to meet other people that have been touched by rare diseases. Learn, engage, and grow with our communities.

FIND YOUR COMMUNITY
Physicians

Our Resources

Our rare disease resources include e-books and podcasts

VIEW OUR EBOOKS

LISTEN TO OUR PODCASTS

VIEW OUR GUIDES

Leaders

Our Community Leaders

Community leaders are active users that have been touched by the rare disease that they are a part of. Not only are they there to help facilitate conversations and provide new information that is relevant for the group, but they are there for you and to let you know you have a support system on Rareshare.